Dáil Éireann Debate, Tuesday - 30 May 2023
742. Deputy Pádraig O'Sullivan asked the Minister for Health if he will outline the bodies consulted in the review by an organisation (details supplied) of the reimbursement system; and if he will make a statement on the matter. [26093/23]
View answerIn February, I published the Mazars Review which examined the governance arrangements around the HSE’s Drug Pricing and Reimbursement Process. As per their Report, the organisation undertook consultation with:
• The Health Service Executive
• Primary Care Reimbursement Service
• The Executive Management Team
• The Drugs Group
• The National Centre for Pharmacoeconomics
• The Department of Public Expenditure and Reform
• The Rare Diseases Technology Review Committee
• The National Cancer Control Programme Technology Review Committee
• Patient representatives via the Rare Diseases Taskforce
